Physician profile
Laura M Devore
NPI 1760227185
$3,704.60
in general payments reported to CMS, 2019-2025
20 companies · $3,359 in 2025
The $3,359 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $345 · 2025: $3,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,704.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $428.95 | 2024-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $363.82 | 2024-2025 | Invega Trinza, Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $313.18 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $311.54 | 2024-2025 | Rexulti |
| Lundbeck LLC | $305.32 | 2024-2025 | Rexulti |
| Alkermes, INC. | $289.21 | 2024-2025 | Aristada, Lybalvi |
| Abbvie INC. | $283.05 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $230.74 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $194.85 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $168.91 | 2024-2025 | Fanapt, Hetlioz |
| Collegium Pharmaceutical, INC. | $156.48 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $153.64 | 2024-2025 | Xelstrym |
| Corium, LLC | $138.98 | 2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $128.84 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $64.98 | 2024-2025 | Trintellix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $61.18 | 2025 | Cobenfy |
| Almatica Pharma LLC | $39.72 | 2025 | Loreev Xr |
| Indivior INC. | $28.06 | 2025 | Sublocade |
| Ironshore Pharmaceuticals INC. | $23.69 | 2024 | |
| Idorsia Pharmaceuticals US INC | $19.46 | 2025 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Devore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.